image
Healthcare - Drug Manufacturers - Specialty & Generic - NYSE - JP
$ 15.33
1.5 %
$ 48.6 B
Market Cap
33.18
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TAK stock under the worst case scenario is HIDDEN Compared to the current market price of 15.3 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TAK stock under the base case scenario is HIDDEN Compared to the current market price of 15.3 USD, Takeda Pharmaceutical Company Limited is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one TAK stock under the best case scenario is HIDDEN Compared to the current market price of 15.3 USD, Takeda Pharmaceutical Company Limited is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart TAK

image
$15.5$15.5$15.0$15.0$14.5$14.5$14.0$14.0$13.5$13.5$13.0$13.0$12.5$12.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
4.26 REVENUE
5.87%
214 B OPERATING INCOME
-56.36%
144 B NET INCOME
-54.56%
716 B OPERATING CASH FLOW
-26.69%
-464 B INVESTING CASH FLOW
23.59%
-354 B FINANCING CASH FLOW
50.02%
1.18 REVENUE
-2.65%
184 B OPERATING INCOME
-16.14%
92 B NET INCOME
-3.36%
259 B OPERATING CASH FLOW
62.51%
-80 B INVESTING CASH FLOW
50.38%
-83.2 B FINANCING CASH FLOW
-25.08%
Balance Sheet Takeda Pharmaceutical Company Limited
image
Current Assets 2.56
Cash & Short-Term Investments 458 B
Receivables 698 B
Other Current Assets 1.4
Non-Current Assets 12.6
Long-Term Investments 431 B
PP&E 1.99
Other Non-Current Assets 10.1
3.03 %4.62 %9.29 %2.85 %13.17 %67.05 %Total Assets$15.1t
Current Liabilities 2.31
Accounts Payable 320 B
Short-Term Debt 367 B
Other Current Liabilities 1.63
Non-Current Liabilities 5.52
Long-Term Debt 5.03
Other Non-Current Liabilities 492 B
4.08 %4.69 %20.75 %64.20 %6.28 %Total Liabilities$7.8t
EFFICIENCY
Earnings Waterfall Takeda Pharmaceutical Company Limited
image
Revenue 4.26
Cost Of Revenue 1.43
Gross Profit 2.83
Operating Expenses 2.62
Operating Income 214 B
Other Expenses 70 B
Net Income 144 B
5t5t4t4t4t4t3t3t3t3t2t2t2t2t1t1t500b500b004t(1t)3t(3t)214b(70b)144bRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
66.43% GROSS MARGIN
66.43%
5.02% OPERATING MARGIN
5.02%
3.38% NET MARGIN
3.38%
1.98% ROE
1.98%
0.95% ROA
0.95%
4.44% ROIC
4.44%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Takeda Pharmaceutical Company Limited
image
1t1t900b900b800b800b700b700b600b600b500b500b400b400b300b300b200b200b100b100b00(100b)(100b)201620162017201720182018201920192020202020212021202220222023202320242024
Net Income 144 B
Depreciation & Amortization 728 B
Capital Expenditures -481 B
Stock-Based Compensation 70.9 B
Change in Working Capital -256 B
Others -24.7 B
Free Cash Flow 236 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Takeda Pharmaceutical Company Limited
image
TAK has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
2.20% DIVIDEND YIELD
0.319 USD DIVIDEND PER SHARE
Q1
Q2
Q3
Q4
0.900000.900000.800000.800000.700000.700000.600000.600000.500000.500000.400000.400000.300000.300000.200000.200000.100000.100000.000000.000000.365290.437050.398920.406430.417170.419050.340.275150.250.240.319160.365320.730.392420.830.399460.800.39550.800.411120.830.430530.850.330.670.270.550.261210.510.270.510.322015201520162016201720172018201820192019202020202021202120222022202320232024202420252025
Download SVG
Download PNG
Download CSV
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Takeda Pharmaceutical Company Limited
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 week ago
TAK vs. DSNKY: Which Stock Is the Better Value Option? Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). zacks.com - 2 weeks ago
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3 LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces that it has earned a 1 million USD milestone payment, following Takeda's (TSE:4502/NYSE:TAK) initiation of Phase 3 clinical trial of mezagitamab (TAK-079), identified from BioInvent's proprietary n-CoDeR® antibody library. The study is evaluating this potential best-in-class anti-CD83 monoclonal antibody for persistent or chronic primary immune thrombocytopenia (ITP). accessnewswire.com - 3 weeks ago
Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 4 weeks ago
Takeda & Protagonist: Rusfertide Clinical Success Bolsters Investment Returns Takeda's AI-powered "returning to growth" program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda's Rusfertide and Protagonist's Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist's financial stability, with a cash runway until 2028, supports a "Strong Buy" rating for high-risk tolerant investors. seekingalpha.com - 1 month ago
TAK vs. DSNKY: Which Stock Should Value Investors Buy Now? Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). zacks.com - 1 month ago
Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
TAK or DSNKY: Which Is the Better Value Stock Right Now? Investors interested in Medical - Drugs stocks are likely familiar with Takeda Pharmaceutical Co. (TAK) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY). zacks.com - 1 month ago
Takeda: Buy Into Future Drug Pipeline Potential, Despite Recent Profit Headwinds Japan-based Takeda Pharmaceutical, which has its ADR listed on the NYSE, gets a buy rating today, agreeing with the analyst consensus. Besides a diverse drug portfolio across multiple segments, they have a robust drug discovery pipeline to meet future clinical demand. The firm has been a proven cash flow generator, with an above-average dividend yield above +4%, and modest leverage risk. seekingalpha.com - 1 month ago
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 1 month ago
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) today announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment. The study met its primary endpoint and all four key secondary endpoints. Rusfertide is a first. businesswire.com - 1 month ago
The European Medicines Agency (EMA) Has Approved an Additional Subcutaneous Administration Option for TAKHZYRO® (lanadelumab) for Patients Aged 12 Years and Above with Recurrent Attacks of Hereditary Angioedema (HAE) TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pen Option is Designed to Allow for An Individualized Treatment Approach for Adolescent and Adult HAE Patients. In the EU, TAKHZYRO is Approved for Routine Prevention of Recurrent HAE Attacks in Patients Aged 2 Years and Older.1 ZURICH , Feb. 24, 2025 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) announced today that the EMA has approved an additional 2 mL pre-filled pen option for TAKHZYRO® (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with Hereditary Angioedema (HAE).1 The additional subcutaneous administration option expands Takeda's offering in this space, showing dedication to the HAE community while providing individualized treatment options to support patients with a life-threatening disease, by helping to reduce HAE burden and improving their Quality of Life. prnewswire.com - 2 months ago
8. Profile Summary

Takeda Pharmaceutical Company Limited TAK

image
COUNTRY JP
INDUSTRY Drug Manufacturers - Specialty & Generic
MARKET CAP $ 48.6 B
Dividend Yield 2.20%
Description Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Contact 1-1, Nihonbashi-Honcho 2-chome, Tokyo, 103-8668 https://www.takeda.com
IPO Date Jan. 5, 2010
Employees 49281
Officers Mr. Christophe Weber President, Chief Executive Officer & Representative Director Mr. Salvatore Alesci M.D., Ph.D. Member of Management Board and Head of R&D Global Science & Biomedical Policy Mr. Iwaaki Taniguchi Senior Vice President of Corporate Finance & Controlling Department Mr. Haruhiko Hirate Member of Management Board Dr. Seigo Izumo Chair of Management Board Mr. Yoshihiro Nakagawa Global General Counsel Mr. Christopher David O'Reilly Global Head of Investor Relations & Global Finance Mr. Gabriele Ricci Chief Data & Technology Officer Mr. Milano Furuta Chief Financial Officer & Director Norimasa Takeda Chief Accounting Officer & Corporate Controller